• Romidepsin: HDAC Biology and HCC Assay Design

  2026-08-23

  Romidepsin (FK228) is a selective class I HDAC inhibitor whose effects extend from histone acetylation to spliceosome stability and DNA-repair sensitivity. This guide translates the HCC reference study into practical assay-design decisions for epigenetic modulation, apoptosis, and combination research.

• MK-5108 (VX-689): Assay Strategy

  2026-08-22

  A scenario-based guide to using MK-5108 (VX-689), SKU A4120, in Aurora-A-focused viability, proliferation, and cytotoxicity studies. It connects biochemical selectivity, DMSO formulation, assay controls, data interpretation, and vendor-selection criteria for more defensible laboratory results.

• Palonosetron hydrochloride Research Workflows

  2026-08-22

  Build sensitive 5-HT3A/5-HT3AB functional assays and OCT2/MATE1 transporter studies with a single, highly selective research tool. This guide translates nanomolar receptor potency, prolonged pharmacology, and transporter activity into practical workflows for cancer research and antiemetic mechanism studies.

• Regorafenib (BAY 73-4506) in Cancer Research

  2026-08-21

  Regorafenib (BAY 73-4506) is an orally active multikinase inhibitor used to study angiogenesis, tumor signaling, invasion, and metastasis. Preclinical evidence links its activity to broad kinase inhibition and, in melanoma, suppression of the RRM2–ERK/E2F3 axis.

• CKI 7 Dihydrochloride: From CK1 to Translation

  2026-08-20

  A translational framework for using CKI 7 dihydrochloride to interrogate Casein kinase 1 biology while connecting Wnt, circadian, apoptosis, and metastasis research without overstating the evidence.

• nor-NOHA Acetate in Cancer Research

  2026-08-20

  nor-NOHA acetate provides a reversible way to perturb arginase-dependent arginine metabolism alongside tumor, immune, and vascular readouts. This workflow guide connects HepG2 and endothelial experiments with a carefully bounded AML immunometabolism extension inspired by CD36 signaling research.

• Hypoxia, Immunometabolism, and the Tumor Microenvironment

  2026-08-19

  This 2025 review integrates tumor hypoxia with immune-cell metabolism to explain how nutrient competition, HIF signaling, and metabolic reprogramming reinforce an immunosuppressive tumor microenvironment. Its main practical contribution is a framework for connecting oxygen limitation and redox-metabolic readouts with tumor progression and the design of metabolism-informed therapeutic strategies.

• Western Secondary Antibody Dilution Buffer: K4115 Guide

  2026-08-19

  Western Secondary Antibody Dilution Buffer K4115 is a formulation for diluting secondary antibodies in Western blot workflows. Its BSA, detergent, and stabilizer composition is intended to reduce non-specific binding and support reuse of diluted antibodies under the product’s stated storage and handling conditions.

• Ceftolozane-Tazobactam in Nosocomial Pneumonia

  2026-08-18

  This review explains why ceftolozane-tazobactam is a valuable option against difficult Gram-negative pneumonia, combining structural features, susceptibility data, PK/PD principles, and ASPECT-NP clinical findings. Its main contribution is linking strong antipseudomonal activity and AmpC stability with time-dependent exposure optimization, while also clarifying important limits against ESBL- and carbapenemase-mediated resistance.

• Everolimus (RAD001): Reading Drug Response Correctly

  2026-08-18

  Everolimus (RAD001) is a mechanistically precise mTOR pathway inhibitor, but its apparent potency depends on whether an assay measures growth arrest, cell death, or both. This guide translates Schwartz’s response-analysis framework into practical cancer research decisions for interpreting proliferation, viability, and apoptosis data.

• AKT Inhibitors: Pharmacology, Resistance, and Combinations

  2026-08-17

  Kostaras and colleagues systematically compared ATP-competitive and allosteric AKT inhibitors using biochemical, cellular, structural, and phosphoproteomic approaches. Their findings show that inhibitor class, AKT isoform, mutation status, and non-catalytic functions can shape response, resistance, and rational drug combinations.

• Atropo-Enantioselective Suzuki Coupling for Rhazinilam

  2026-08-17

  Herrbach and co-workers developed a catalytic asymmetric route to an axially chiral rhazinilam analogue using an intermolecular Suzuki coupling. Screening identified binaphthyl ligand 7a as the most effective ligand in the reported series, giving the nonbridged biaryl precursor with up to 40% enantiomeric excess and establishing a useful precedent for biologically relevant atroposelective synthesis.

• PPARα Activation Blocks Pyroptosis in Cholestatic Injury

  2026-08-16

  A 2026 Liver Research study identifies two pyroptotic programs suppressed by PPARα activation in lithocholic acid-induced cholestatic liver injury. By combining histopathology, electron microscopy, biochemical assays, gene and protein analyses, and co-immunoprecipitation, the work connects PPARα signaling with NLRP3/NF-κB and APAF1/CASPASE-3/GSDME/FOXO1 pathways.

• IDH1-R132H Autopalmitoylation in Cancer Cells

  2026-08-15

  The reference study identifies C269 autopalmitoylation as a mutation-associated regulatory mechanism that enhances IDH1-R132H substrate and cofactor binding, dimerization, and neomorphic 2-HG production. By combining chemical-probe chemoproteomics, cysteine mutagenesis, biochemical assays, and cellular phenotyping, the work connects fatty acid metabolism with IDH1-mutant oncogenic activity and highlights a potentially druggable hydrophobic pocket.

• WY-14643: PPARα Workflow for Metabolic Research

  2026-08-14

  WY-14643 (Pirinixic Acid) provides a controlled way to interrogate PPARα-driven lipid metabolism, endothelial inflammation, and insulin sensitivity enhancement. Its strongest use-case is as a mechanistic perturbation tool that connects receptor activation with multiomics, cell-based assays, and translational metabolic phenotypes.

7907 records 1/528 page Next 12345 下5页 Last page